MannKind Corporation is committed to the development of innovative pharmaceutical products that address significant unmet medical needs. In the development of those products, clinical trials are conducted to determine their safety and efficacy in order to be approved for use by patients.
MannKind has an ethical obligation to publish information about clinical trials for our own investigational products. We publish information on our clinical trials in scientific journals and participate in the clinical trials registry at www.clinicaltrials.gov. MannKind ensures ethical and safe conduct to protect all subjects in its clinical trials. MannKind posts protocol information for all Phase 2 and 3 MannKind-sponsored clinical studies.
AFREZZA® is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. For more information please visit www.clinicaltrials.gov.
MKC1106 - MT is being evaluated in a phase 2 clinical trial for patients with advanced melanoma. For more information please visit www.clinicaltrials.gov